Physician profile
Brent Egan
NPI 1376634998
$1,815.26
in general payments reported to CMS, 2019-2025
21 companies · $313 in 2025
The $313 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $380 · 2022: $447 · 2023: $384 · 2024: $291 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $988.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $988.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $572.13 | 2021-2025 | Xtampza, Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $319.64 | 2022-2025 | Relistor, Trulance |
| Abbvie INC. | $151.91 | 2021-2023 | |
| Pfizer INC. | $102.06 | 2023-2025 | |
| Indivior INC. | $85.04 | 2022-2025 | Sublocade |
| Amgen INC. | $70.44 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $67.86 | 2022 | |
| Biodelivery Sciences International, INC. | $57.79 | 2021 | |
| Virtus Pharmaceuticals LLC | $57.39 | 2021 | |
| Nevro Corp. | $44.83 | 2024 | Senza |
| Azurity Pharmaceuticals, INC. | $43.34 | 2023-2024 | Horizant, Horizant |
| Merz North America, INC. | $42.87 | 2022 | |
| Relievant Medsystems, INC. | $30.46 | 2021 | |
| Redhill Biopharma INC. | $28.55 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $28.09 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $27.93 | 2021 | |
| Grt US Holding, INC. | $22.33 | 2021 | |
| Bioventus LLC | $19.59 | 2023 | Durolane |
| Merck Sharp & Dohme LLC | $16.90 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $13.80 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $12.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brent Egan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.